Compare Summit Therapeutics Inc (SMMT) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Wipro Limited — how do they compare? Summit Therapeutics Inc trades at $17.33 (market cap $14.33B), while Wipro Limited trades at $1.69 (market cap $16.36B). The key difference: Summit Therapeutics Inc and Wipro Limited are close in size by market cap, and Wipro Limited pays a 5.19% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Wipro Limited for 41 Days on average.
| SMMT | WIT | |
|---|---|---|
Market Cap | $14.33B | $16.36B |
Volume | 8,167,213 | 6,583,554 |
Sector | Health | Technology |
52-Week High | $26.38 | $3.06 |
52-Week Low | $12.43 | $1.61 |
Typical Hold Time | 16 Days | 41 Days |
Enterprise Value | $13.66B | $14.47B |
Dividend Yield | — | 5.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.95, up 3.7% today, with a bullish technical signal from moving averages and a consensus analyst price target of $29.33. The stock has surged recently following a $2 billion strategic equity investment from AstraZeneca and expanded clinical collaborations. However, the company remains pre-revenue with significant losses, reflected in a negative ROE of -192.5% and negative EBITDA of -$1.08 billion for 2025.
The outlook is driven by clinical progress for ivonescimab, but high execution risk and cash burn necessitate close monitoring. Investment opportunity hinges on successful drug development, while key risks include trial outcomes and funding needs. The stock offers high-risk, high-reward potential based on pipeline milestones.
Wipro (WIT) trades at $1.67, down 0.6% with bearish technical signals despite recent AI productivity gains. The company reported $890.88B revenue for 2025 with solid 13.92% net margins and reasonable valuation (P/E 12.78). Recent quarters show earnings misses, but cash flow remains strong at $25.02B. Analyst sentiment is mixed with only 19% buy ratings.
Wipro faces execution risks amid competitive IT services market, though AI initiatives show promise. The stock offers value pricing but requires earnings acceleration to justify higher multiples. Near-term performance depends on client spending recovery and AI deployment success.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
